{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T12:35:06Z","timestamp":1761741306854,"version":"build-2065373602"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,9,9]],"date-time":"2019-09-09T00:00:00Z","timestamp":1567987200000},"content-version":"vor","delay-in-days":251,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics"],"published-print":{"date-parts":[[2019]]},"DOI":"10.6061\/clinics\/2019\/e771","type":"journal-article","created":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T16:56:32Z","timestamp":1568307392000},"page":"e771","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Prolonged response to recombinant human erythropoietin treatment in patients with myelodysplastic syndrome at a single referral centre in Brazil"],"prefix":"10.1016","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6582-7867","authenticated-orcid":false,"given":"Anna Thawanny Gadelha","family":"Moura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5170-695X","authenticated-orcid":false,"given":"Fernando Barroso","family":"Duarte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8980-5638","authenticated-orcid":false,"given":"Maritza Cavalcante","family":"Barbosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4167-6491","authenticated-orcid":false,"given":"Talyta Ellen","family":"de Jesus dos Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3178-412X","authenticated-orcid":false,"given":"Rom\u00e9lia Pinheiro Gon\u00e7alves","family":"Lemes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"17","key":"10.6061\/clinics\/2019\/e771_bib1","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1182\/blood-2013-03-492884","article-title":"Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet","volume":"122","author":"Malcovati","year":"2013","journal-title":"Blood"},{"issue":"2","key":"10.6061\/clinics\/2019\/e771_bib2","first-page":"136","article-title":"Quality of life and physicians\u2019 perception in myelodysplastic syndromes","volume":"2","author":"Oliva","year":"2012","journal-title":"Am J Blood Res"},{"issue":"11","key":"10.6061\/clinics\/2019\/e771_bib3","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/j.leukres.2010.05.030","article-title":"Early introduction of ESA in low risk MDS patients may delay the need for RBC transfusion: a retrospective analysis on 112 patients","volume":"34","author":"Park","year":"2010","journal-title":"Leuk Res"},{"issue":"2","key":"10.6061\/clinics\/2019\/e771_bib4","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1182\/blood-2007-06-096370","article-title":"Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G\u2010CSF: the GFM experience","volume":"111","author":"Park","year":"2008","journal-title":"Blood"},{"issue":"21","key":"10.6061\/clinics\/2019\/e771_bib5","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1200\/JCO.2007.15.4906","article-title":"Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome","volume":"26","author":"Jadersten","year":"2008","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.6061\/clinics\/2019\/e771_bib6","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1517\/14712591003709713","article-title":"Darbepoetin alfa in anemia of myelodysplastic syndromes: present and beyond","volume":"10","author":"Kelaidi","year":"2010","journal-title":"Expert Opin Biol Ther"},{"issue":"Suppl 1","key":"10.6061\/clinics\/2019\/e771_bib7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1054\/bjoc.2001.1746","article-title":"Development and characterization of novel erythropoiesis stimulating protein (NESP)","volume":"84","author":"Egrie","year":"2001","journal-title":"Br J Cancer"},{"issue":"2","key":"10.6061\/clinics\/2019\/e771_bib8","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s11095-010-0288-2","article-title":"Quality of original and biosimilar epoetin products","volume":"28","author":"Brinks","year":"2011","journal-title":"Pharm Res"},{"issue":"9","key":"10.6061\/clinics\/2019\/e771_bib9","first-page":"1324","article-title":"Prediction of response to treatment with human recombinant erythropoietin in myelodysplastic syndromes","volume":"7","author":"Stenke","year":"1993","journal-title":"Leukemia"},{"issue":"Suppl 3","key":"10.6061\/clinics\/2019\/e771_bib10","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1634\/theoncologist.2011-S3-35","article-title":"Clinical use of erythropoietic stimulating agents in myelodysplastic syndromes","volume":"16","author":"Santini","year":"2011","journal-title":"Oncologist"},{"issue":"6","key":"10.6061\/clinics\/2019\/e771_bib11","doi-asserted-by":"crossref","first-page":"720","DOI":"10.20344\/amp.6518","article-title":"[Serum Erythropoietin as Prognostic Marker in Myelodysplastic Syndromes]","volume":"28","author":"Cortes\u00e3o","year":"2015","journal-title":"Acta Med Port"},{"issue":"6","key":"10.6061\/clinics\/2019\/e771_bib12","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.leukres.2006.11.009","article-title":"Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference","volume":"31","author":"Valent","year":"2007","journal-title":"Leuk Res"},{"issue":"2","key":"10.6061\/clinics\/2019\/e771_bib13","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia","volume":"108","author":"Cheson","year":"2006","journal-title":"Blood"},{"issue":"10","key":"10.6061\/clinics\/2019\/e771_bib14","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1634\/theoncologist.12-10-1264","article-title":"Efficacy and safety of erythropoiesis-stimulating proteins in myelodysplastic syndrome: a systematic review and meta-analysis","volume":"12","author":"Ross","year":"2007","journal-title":"Oncologist"},{"issue":"5","key":"10.6061\/clinics\/2019\/e771_bib15","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00277-013-1686-4","article-title":"High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower\u2010risk myelodysplastic syndromes: a phase II study by the GFM","volume":"92","author":"Kelaidi","year":"2013","journal-title":"Ann Hematol"},{"issue":"Suppl 1","key":"10.6061\/clinics\/2019\/e771_bib16","first-page":"248","article-title":"Randomized, double-blind, placebo-controlled, multicenter study, evaluating Epoetin-alfa versus placebo in anemic patients with IPSS Low-Int1 risk MDS [abstract]","volume":"101","author":"Fenaux","year":"2016","journal-title":"Haematologica"},{"issue":"9","key":"10.6061\/clinics\/2019\/e771_bib17","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1038\/leu.2017.192","article-title":"A phase 3 randomised placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes","volume":"31","author":"Platzbecker","year":"2017","journal-title":"Leukemia"},{"issue":"3","key":"10.6061\/clinics\/2019\/e771_bib18","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/joim.12579","article-title":"Erythropoiesis\u2010stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower\u2010risk myelodysplastic syndrome","volume":"281","author":"Garelius","year":"2017","journal-title":"J Intern Med"},{"issue":"2","key":"10.6061\/clinics\/2019\/e771_bib19","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1046\/j.1365-2141.2003.04435.x","article-title":"Efficacy of a single, weekly dose of recombinant erythropoietin in myelodysplastic syndromes","volume":"122","author":"Musto","year":"2003","journal-title":"Br J Haematol"},{"issue":"7","key":"10.6061\/clinics\/2019\/e771_bib20","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/ajh.21178","article-title":"Bone marrow glycophorin-positive erythroid cells of myelodysplastic patients responding to high-dose rHuEPO therapy have a different gene expression pattern from those of nonresponders","volume":"83","author":"Cortelezzi","year":"2008","journal-title":"Am J Hematol"},{"issue":"11","key":"10.6061\/clinics\/2019\/e771_bib21","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/j.leukres.2011.05.025","article-title":"Weekly standard doses of rh-EPO are highly effective for the treatment of anemic patients with low-intermediate 1 risk myelodysplastic syndromes","volume":"35","author":"Balleari","year":"2011","journal-title":"Leuk Res"},{"author":"National Comprehensive Cancer Network (NCCN)","key":"10.6061\/clinics\/2019\/e771_bib22"},{"issue":"4","key":"10.6061\/clinics\/2019\/e771_bib23","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1053\/j.seminhematol.2015.06.002","article-title":"Anemia as the main manifestation of myelodysplastic syndromes","volume":"52","author":"Santini","year":"2015","journal-title":"Semin Hematol"},{"issue":"17","key":"10.6061\/clinics\/2019\/e771_bib24","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1182\/blood-2012-03-415661","article-title":"Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome","volume":"120","author":"Komrokji","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.6061\/clinics\/2019\/e771_bib25","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.leukres.2011.11.019","article-title":"Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?","volume":"36","author":"Itzykson","year":"2012","journal-title":"Leuk Res"},{"issue":"2","key":"10.6061\/clinics\/2019\/e771_bib26","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.blre.2007.10.003","article-title":"Supportive care, growth factors, and new therapies in myelodysplastic syndromes","volume":"22","author":"Hellstr\u00f6m-Lindberg","year":"2008","journal-title":"Blood Rev"},{"issue":"7","key":"10.6061\/clinics\/2019\/e771_bib27","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.leukres.2007.11.037","article-title":"Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide","volume":"32","author":"Kelaidi","year":"2008","journal-title":"Leuk Res"},{"issue":"12","key":"10.6061\/clinics\/2019\/e771_bib28","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.6061\/clinics\/2019\/e771_bib29","article-title":"Rare cytogenetic abnormalities in myelodysplastic syndromes","volume":"7","author":"Bacher","year":"2015","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"3","key":"10.6061\/clinics\/2019\/e771_bib30","first-page":"182","article-title":"Chromosomal abnormalities in myelodysplastic syndrome","volume":"28","author":"Chauffaille","year":"2006","journal-title":"Rev Bras hematol hemoter"},{"issue":"11","key":"10.6061\/clinics\/2019\/e771_bib31","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V108.11.4867.4867","article-title":"Unexpected response to erythropoietin therapy in intermediate-low IPSS myelodysplastic syndromes","volume":"108","author":"Kwon","year":"2006","journal-title":"Blood"}],"container-title":["Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593222006500?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593222006500?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T06:59:18Z","timestamp":1761721158000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1807593222006500"},"secondary":[{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S1807-59322019000100263&lng=en&nrm=iso&tlng=en","label":"SCIELO"},{"URL":"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6724462\/","label":"PMC"},{"URL":"https:\/\/www.clinicsjournal.com\/article\/prolonged-response-to-recombinant-human-erythropoietin-treatment-in-patients-with-myelodysplastic-syndrome-at-a-single-referral-centre-in-brazil\/","label":"CLINICS"}]},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":31,"alternative-id":["S1807593222006500"],"URL":"https:\/\/doi.org\/10.6061\/clinics\/2019\/e771","relation":{},"ISSN":["1807-5932"],"issn-type":[{"type":"print","value":"1807-5932"}],"subject":[],"published":{"date-parts":[[2019]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prolonged response to recombinant human erythropoietin treatment in patients with myelodysplastic syndrome at a single referral centre in Brazil","name":"articletitle","label":"Article Title"},{"value":"Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.6061\/clinics\/2019\/e771","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2019 CLINICS. Published by Elsevier Spain","name":"copyright","label":"Copyright"}],"article-number":"e771"}}